Subscribe Now
Trending News

Blog Post


Major Advances in HIV Prevention 

Researchers have been working nonstop since late 2018 to get to the bottom of the current pandemic, Covid-19. Several vaccinations have been created, and others are still being developed in different regions of the world.

Despite all of these noble efforts to save humanity, some scientists have achieved major breakthroughs in HIV and Aids research.

In recent years, scientists have made three major breakthroughs in the fight against HIV and Aids, which has affected over 38 million people worldwide.

Administered PrEP Injections

Women using long-acting cabotegravir injections had 89 percent fewer HIV infections than women taking daily Prep, according to research performed in seven African nations. Professor Sinead Delany-Moretlwe of the University of Witwatersrand in South Africa conducted the study

Despite the fact that many research has shown that HIV oral tablets are beneficial, people fighting the never-ending discrimination have found it difficult to stick to the daily doses.

The PrEP injection will assist to lower the risk of HIV and Aids infection, particularly in individuals who are in high-prevalence areas. The injection will be given once a month and will benefit people who experience everyday prejudice because of their status, such as sex workers and divorcing spouses.

In the study communities, HIV incidence is around 3.5 percent each year in the absence of effective preventive measures. It was 1.9 percent in the oral PrEP arm and 0.2 percent in the injectable PrEP arm in the study.

Injections for HIV patients once a month.

ViiV Healthcare’s injectable Cabenuva medication, which contains cabotegravir and rilpivirine, has been authorized by the US Food and Drug Administration (FDA) for the treatment of HIV infection in adults.

Cabenuva injection is intended to replace HIV-infected individuals’ daily antiretroviral treatment. Cabenuva combines cabotegravir, an inhibitor of HIV integrase strand transfer, with rilpivirine, an inhibitor of HIV non-nucleoside reverse transcriptase.

The medication is successful in suppressing HIV, according to a 48-week trial involving 1,100 patients from 16 countries.

The finding will benefit people who find it difficult to carry their medications with them, as well as those who deal with the disease’s everyday stigma.

Mild adverse effects of the injection were noted by individuals who were tested, including headache, tiredness, sleep disturbance, dizziness, rash, and pyrexia.

Ring around the vagina

For decades, safe sex practices have been the most effective approach to prevent people from HIV and Aids infection, particularly among women and girls.

In today’s globe, women account for more than half of all HIV and Aids patients. According to recent research, women account for 60% of people infected with HIV and Aids in Sub-Saharan Africa.

The Dapivirine Vaginal Ring (DPV-VR), a women’s-tailored vaginal ring, has been on the market for a while and has helped women avoid HIV infections.

The ring has been shown to reduce HIV risks by 35%, with recent findings from open-label extension trials showing an even higher decrease in HIV risk of around 50%.

Related posts

Leave a Reply

Required fields are marked *